In Brief
FDA Approves Novel Nonopioid Treatment for Moderate-to-Severe Acute Pain
The FDA has approved suzetrigine (Journavx, Vertex Pharmaceuticals) 50 mg oral tablets as a first-in-class nonopioid analgesic to treat all types of moderate-to-severe acute pain in adults.
JANUARY 31, 2025
NIH Ends Study of Tecovirimat as Mpox Pain Treatment
The NIH has halted a study testing tecovirimat as a treatment for patients with mpox after the drug showed no significant difference in reducing the time to lesion resolution or in influencing pain compared with placebo.
JANUARY 27, 2025
Better Algorithms Needed for Predicting Opioid Use Disorder
There is a need for more robust data and improved machine learning techniques to accurately assess the genetic risk of developing OUD, according to new research.
JANUARY 17, 2025
FDA Issues New Guidance, Clarifies Confusion on Buprenorphine Labeling
The FDA has issued new guidance for labeling buprenorphine-containing transmucosal products that seeks to clarify misinterpreted packaging.
JANUARY 16, 2025
FDA Grants 510(k) Clearance for Updated Cryoneurolysis System for LBP
The ioveraº system is an FDA-cleared, drug-free treatment that relieves pain via cryoneurolysis.
JANUARY 14, 2025
Patients, Providers Provide Perspectives on Opioid Diversion in Canada’s Safer Supply Programs
Safer pharmaceutical-grade alternatives to toxic and unregulated supplies of opioids could help address opioid diversion issues for patients to better prevent overdoses and other harms linked to the toxic drug supply.
JANUARY 9, 2025
FDA Approves Atogepant to Prevent Chronic Migraine in Adults
Atogepant becomes the first oral CRGP receptor antagonist approved to prevent both episodic and chronic migraine.
APRIL 19, 2023
FDA Grants De Novo Status to Opioid Overdose Prevention and Alert System
Opioid Halo will be available OTC and by prescription
APRIL 12, 2023
FDA Accepts sNDA for Nerve Blocks in Lower Extremity Procedures
The label expansion would include single-dose sciatic nerve block in the popliteal fossa and femoral nerve block in the adductor canal.
APRIL 11, 2023
Biosimilar Approved to Treat Moderate to Severe RA
The FDA has approved rituximab-arrx for adults with moderate to severe active RA.
JUNE 8, 2022
FDA Grants sNDA Extension to Investigational Endometriosis Pain Drug
The FDA extended the review period for relugolix for the management of moderate to severe pain associated with endometriosis.
MAY 19, 2022
Upadacitinib Approved for Adults With Active Ankylosing Spondylitis
The FDA approved upadacitinib for the treatment of adults with active ankylosing spondylitis who have had an inadequate response or intolerance to one or more TNF blocker.
MAY 4, 2022